Leaders in radioconjugates for oncology, like Fusion Pharmaceuticals, have drawn industry attention to Canada. Thanks to Canadian Medical Isotope Ecosystem, we are eager to advance the development of a targeted radioconjugate program (https://lnkd.in/g2rjuHns). Connect with us at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting! #SNMMI24
ProteinQure
Biotechnology Research
Toronto, Ontario 5,307 followers
Peptide-based drug delivery.
About us
ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering.
- Website
-
https://www.proteinqure.com/
External link for ProteinQure
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
119 Spadina Ave
304
Toronto, Ontario M5V 2L1, CA
Employees at ProteinQure
Updates
-
ProteinQure is in Chicago for #ASCO24 to discuss the next-generation of cancer treatment. Connect with Lucas Siow or Francine E. Lui, Ph.D. to discuss the road map to bring our peptide-drug conjugate to the patients who need it.
-
-
ProteinQure reposted this
Excited to leverage this opportunity to continue to advance our first internal radio-peptide conjugate program. Ontario and Canada have had some major wins radiopharma (point, fusion amongst others). Hoping to build on their great examples.
We are proud to announce the successful conclusion of our first Call for Proposals! Five programs from across Canada were selected and will receive in total over $1.7M in funding. The selected projects represent a diverse range of medical isotope innovations aimed at addressing critical healthcare needs across Canada and beyond. Applicants spanned from Coast to Coast, with companies with winning programs including, ACT225 BioTherapeutics Corporation (Saskatchewan), Ottawa Heart Institute (Ontario), ProteinQure(Ontario), Synergy Oncology (Nova Scotia), and Yellowbird Diagnostics, Inc. (Ontario). Click to learn more: https://lnkd.in/g2rjuHns
-
ProteinQure reposted this
Curious how personalized medicine is transforming the future of cancer care? On June 12, #MaRSImpactHealth explores precision oncology’s funding frenzy and the market opportunities for these complex cancer treatments. Register now: https://lnkd.in/eYYprcve. Ft. Francine E. Lui, Ph.D. (principal scientist, ProteinQure), Smruthi Vijayaraghavan, Ph.D. (director, head of solid tumor (lung) oncology discovery, Johnson & Johnson), Dozie Amuzie (head, JLABS Canada), Laszlo Radvanyi (president and scientific director, Ontario Institute for Cancer Research) and Ratmir Derda (CSO, 48Hour Discovery and professor, University of Alberta).
-
-
Find us at #TIDESUSA 2024 this week to discuss targeted drug delivery. Our CEO Lucas Siow will be presenting unpublished in vivo data from our siRNA delivery program on May 16th.
-
-
Our CEO is attending the Align Summit in Boston this week. A conference that highlights the best AI Drug discovery startups in North America. Hope to see you there!
Time is running out! Don't miss the chance to witness ProteinQure present at @MassBio 2024 Align Summit with insights by @McKinsey and @Locust Walk. Register for a full day of panel discussions, presentations by seed/series A #biotech and emerging artificial intelligence/machine learning companies, plus lots of networking. https://lnkd.in/g5EuQD4e #AlignSummit24 #AlignSummit #AIDrugDiscovery I will also be in Boston Friday, catching up with old friends and new ones.
2024 Align Summit - MassBio
https://www.massbio.org
-
Excited to announce that our CEO Lucas Siow, is currently attending the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto. We're eager to meet with investors, partners, and scientists. Reach out about #oncology, drug delivery, or #peptides. Let's connect! #BBHIC2024
-
-
We are pleased to announce that ProteinQure, in collaboration with leading researchers at UHN Princess Margaret Cancer Centre, will present significant findings related to our breast cancer program at the forthcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community. Presentation Details: Title: In-vivo Efficacy of a Novel Peptide-Conjugated Drug in Patient-Derived Xenograft Models of Breast Cancer Session: New Targets Date/Time: Tuesday, April 9, 1:30 p.m. PT / 4:30 p.m. ET Abstract Number: 5911 Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre We are looking forward to sharing our insights with the cancer research community at AACR and contributing to the ongoing efforts to combat breast cancer through innovative research. https://tinyurl.com/PQInc #AACR2024 #BreastCancerResearch #ComputationalDrugDesign #InnovationInHealthcare #ProteinQure #PeptideTherapeutics
-
-
We’re thrilled to share that ProteinQure, in collaboration with Dr. David Cescon’s Lab at the Princess Margaret Cancer Centre, has made a significant breakthrough in the fight against Triple-Negative Breast Cancer (TNBC). Our development of a novel Peptide Drug Conjugate (PDC) has demonstrated remarkable effectiveness across a range of patient-derived mouse models. Leveraging advanced computational methods, ProteinQure has crafted a tumor-targeting PDC that pairs a novel peptide with a potent chemotherapeutic agent, showcasing remarkable antitumor activity, even in chemoresistant cancers. This achievement paves the way for our lead program to progress into IND-enabling studies and clinical trials and its result will be presented at the upcoming American Association for Cancer Research Annual Meeting. Stay tuned for further details from the AACR presentation on April 9, 2024. We are grateful for the support from National Research Council Canada / Conseil national de recherches Canada & INOVAIT Canada. #AACR2024 #BreastCancerResearch #ComputationalDrugDesign #InnovationInHealthcare #ProteinQure #PeptideTherapeutics https://tinyurl.com/PQInc
ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR
accesswire.com
-
🚀 Big News from ProteinQure! 🚀 Exciting update: ProteinQure, has validated our lead program for triple-negative breast cancer (TNBC) and I'm thrilled to announce that our findings will be presented at the upcoming AACR conference in San Diego, showcasing our commitment to advancing cancer research (see press release for poster details). Our novel Peptide Drug Conjugate (PDC) has shown exceptional efficacy in battling TNBC, even in treatment-resistant cases. Performed at Dr. David Cescon's lab at Princess Margaret Cancer Centre/University Health Network, our PDC demonstrated remarkable results in over 15 heterogeneous Patient-Derived Xenograft (PDX) models. As a computational drug discovery company, it has been amazing to stop trying to convince people with benchmarks on irrelevant data sets and start pointing to multiple drug candidates that ProteinQure has enabled. We are looking forward to collaborating further with world-class clinicians on our Phase I clinical trial in the near future. I will be at AACR to learn from and speak to researchers about our development candidate and planned FIH trial. #ProteinQure #CancerResearch #AACR2024 #PrecisionMedicine #DrugDevelopment #AIDrugDiscovery https://lnkd.in/geZTFMtY
ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR
accesswire.com